During end stage renal disease (ESRD) inflammatory pathways are activated which may lead to malnutrition inflammation syndrome (MIS). In the present study, 257 ESRD patients and 200 controls were included. Cytokine levels and genotyping was done by polymerase chain reaction–restriction fragment length polymorphism and enzyme-linked immunosorbent assay (ELISA). Risk was estimated through binary logistic regression. Cox proportional hazards regression and Kaplan–Meier were used for survival analysis. Tumor necrosis factor TNF-α-308 AA conferred 3.6-fold higher susceptibility (P=0.001) and higher TNF-α levels (P=0.05). TNF-α-238 AA was associated with 3.3-fold higher susceptibility to ESRD (P=0.002). IL-6-174 CC genotype conferred 3-fold risk to disease (P=0.001) along with higher IL-6 levels (P=0.001). IL-10-1082 GG genotype exhibited 2.2-fold higher susceptibility to disease (P=0.013). IL-10-592 AA/-819 TT genotypes were associated with high C reactive protein (P=0.02) and low IL-10 (P=0.03) levels. TNF-α-308 A allele was significantly associated with 2.3-fold higher risk of malnutrition. TNF-α-GAC, AGC and IL-6-CC were risk haplotypes associated with higher disease susceptibility. Combined analysis revealed 1.6-fold higher susceptibility to disease (P=0.02), there was 2-fold higher susceptibility to malnutrition (P=0.02) in high inflammation group. TNF-α-238 AA genotype was associated with 2.5-fold higher death hazard risk (P=0.02). Our study suggests that TNF-α and its genetic variants are major contributors to susceptibility to MIS in ESRD patients.
Get full access to this article
View all access options for this article.
References
1.
AcharyyaS, GuttridgeDC. 2007. Cancer cachexia signaling pathways continue to emerge yet much still points to the proteasome. Clin Cancer Res, 13,5:1356–1361.
2.
AkerS, BantisC, ReisP, KuhrN, SchwandtC, GrabenseeB, HeeringP, IvensK. 2009. Influence of interleukin-6 g-174c gene polymorphism on coronary artery disease, cardiovascular complications and mortality in dialysis patients. Nephrol Dial Transplant, 24,9:2847–2851.
3.
ArgilesJM, BusquetsS, ToledoM, Lopez-SorianoFJ. 2009. The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care, 3,4:263–268.
4.
BalakrishnanVS, GuoD, RaoM, JaberBL, TighiouartH, FreemanRL, HuangC, KingAJ, PereiraBJ. 2004. Cytokine gene polymorphisms in hemodialysis patients: association with comorbidity, functionality, and serum albumin. Kidney Int, 65,4:1449–1460.
5.
BlumenkrantzMJ, KoppleJD, GutmanRA, ChanYK, BarbourGL, RobertsC, ShenFH, GandhiVC, TuckerCT, CurtisFK, CoburnJW. 1980. Methods for assessing nutritional status of patients with renal failure. Am J Clin Nutr, 33,7:1567–1585.
6.
DantzerRK, KelleyW. 2007. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun, 21,2:153–160.
7.
DeansDA, TanBH, RossJA, Rose-ZerilliM, WigmoreSJ, HowellWM, GrimbleRF, FearonKC. 2009. Cancer cachexia is associated with the IL10-1082 gene promoter polymorphism in patients with gastroesophageal malignancy. Am J Clin Nutr, 89,4:1164–1172.
8.
Descamps-LatschaB, HerbelinA, NguyenAT, Roux-LombardP, ZingraffJ, MoynotA, VergerC, DahmaneD, de GrooteD, JungersPet al.1995. Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of t cells, b cells, and monocytes. J Immunol, 154,2:882–892.
9.
EskdaleJ, GallagherG. 1995. A polymorphic dinucleotide repeat in the human IL-10 promoter. Immunogenetics, 42,5:444–445.
10.
FockRA, VinoloMA, CrismaAR, NakajimaK, RogeroMM, BorelliP. 2008. Protein-energy malnutrition modifies the production of interleukin-10 in response to lipopolysaccharide (LPS) in a murine model. J Nutr Sci Vitaminol (Tokyo), 54,5:371–377.
11.
FujikiF, MukaidaN, HiroseK, IshidaH, HaradaA, OhnoS, BluethmannH, KawakamiM, AkiyamaM, SoneS, MatsushimaK. 1997. Prevention of adenocarcinoma colon 26-induced cachexia by interleukin 10 gene transfer. Cancer Res, 57,1:94–99.
12.
GaudermanWJ. 2002. Sample size requirements for association studies of gene-gene interaction. Am J Epidemiol, 155,5:478–484.
13.
GaudinoM, AndreottiF, ZamparelliR, Di CastelnuovoA, NassoG, BurzottaF, IacovielloL, DonatiMB, SchiavelloR, MaseriA, PossatiG. 2003. The −174g/c interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication?Circulation, 108,Suppl 1:II195–199.
14.
GuttridgeDC, MayoMW, MadridLV, WangCY, BaldwinASJr. 2000. NF-kappab-induced loss of myod messenger rna: Possible role in muscle decay and cachexia. Science, 289,5488:2363–2366.
15.
JaberBL, RaoM, GuoD, BalakrishnanVS, PerianayagamMC, FreemanRB, PereiraBJ. 2004. Cytokine gene promoter polymorphisms and mortality in acute renal failure. Cytokine, 25,5:212–219.
16.
JagerKJ, MerkusMP, HuismanRM, BoeschotenEW, DekkerFW, KorevaarJC, TijssenJG, KredietRT. 2001. Nutritional status over time in hemodialysis and peritoneal dialysis. J Am Soc Nephrol, 12,6:1272–1279.
17.
KaizuY, OhkawaS, OdamakiM, IkegayaN, HibiI, MiyajiK, KumagaiH. 2003. Association between inflammatory mediators and muscle mass in long-term hemodialysis patients. Am J Kidney Dis, 42,2:295–302.
18.
Kalantar-ZadehK, BlockG, McAllisterCJ, HumphreysMH, KoppleJD. 2004. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr, 80,2:299–307.
19.
Kalantar-ZadehK, KoppleJD, HumphreysMH, BlockG. 2004. Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients. Nephrol Dial Transplant, 19,6:1507–1519.
20.
KamimuraMA, DraibeSA, DalboniMA, CendorogloM, AvesaniCM, ManfrediSR, CanzianiME, CuppariL. 2007. Serum and cellular interleukin-6 in haemodialysis patients: relationship with energy expenditure. Nephrol Dial Transplant, 22,3:839–844.
21.
LavianoA, KrznaricZ, Sanchez-LaraK, PreziosaI, CascinoA, Rossi FanelliF. 2010. Chronic renal failure, cachexia, and ghrelin. Int J Pept10.1155/2010/648045
22.
LositoA, KalidasK, SantoniS, JefferyS. 2003. Association of interleukin-6-174g/c promoter polymorphism with hypertension and left ventricular hypertrophy in dialysis patients. Kidney Int, 64,2:616–622.
23.
MitchWE, DuJ, BaileyJL, PriceSR. 1999. Mechanisms causing muscle proteolysis in uremia: the influence of insulin and cytokines. Miner Electrolyte Metab, 25,4–6:216–219.
24.
MonkJM, SteevelsTA, HillyerLM, WoodwardB. 2011. Constitutive, but not challenge-induced, interleukin-10 production is robust in acute pre-pubescent protein and energy deficits: new support for the tolerance hypothesis of malnutrition-associated immune depression based on cytokine production in vivo. Int J Environ Res Public Health, 8,1:117–135.
25.
MoritaY, YamamuraM, KashiharaN, MakinoH. 1997. Increased production of interleukin-10 and inflammatory cytokines in blood monocytes of hemodialysis patients. Res Commun Mol Pathol Pharmacol, 98,1:19–33.
26.
Muller-SteinhardtM, EbelB, HartelC. 2007. The impact of interleukin-6 promoter−597/-572/-174genotype on interleukin-6 production after lipopolysaccharide stimulation. Clin Exp Immunol, 147,2:339–345.
PanichiV, MaggioreU, TaccolaD, MiglioriM, RizzaGM, ConsaniC, BertiniA, SposiniS, Perez-GarciaR, RindiP, PallaR, TettaC. 2004. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than c-reactive protein in haemodialysis patients. Nephrol Dial Transplant, 19,5:1154–1160.
29.
PearsonTA, MensahGA, AlexanderRW, AndersonJL, CannonRO3rd, CriquiM, FadlYY, FortmannSP, HongY, MyersGL, RifaiN, SmithSCJr., TaubertK, TracyRP, VinicorF. 2003. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the american heart association. Circulation, 107,3:499–511.
30.
Plata-SalamanCR, OomuraY, KaiY. 1988. Tumor necrosis factor and interleukin-1 beta: suppression of food intake by direct action in the central nervous system. Brain Res, 448,1:106–114.
31.
RanganathP, TripathiG, SharmaRK, SankhwarSN, AgrawalS. 2009. Role of non-HLA genetic variants in end-stage renal disease. Tissue Antigens, 74,2:147–155.
32.
SpriewaldBM, WitzkeO, WassmuthR, WenzelRR, ArnoldML, PhilippT, KaldenJR. 2005. Distinct tumour necrosis factor alpha, interferon gamma, interleukin 10, and cytotoxic t cell antigen 4 gene polymorphisms in disease occurrence and end stage renal disease in wegener's granulomatosis. Ann Rheum Dis, 64,3:457–461.
33.
StenlofK, WernstedtI, FjallmanT, WalleniusV, WalleniusK, JanssonJO. 2003. Interleukin-6 levels in the central nervous system are negatively correlated with fat mass in overweight/obese subjects. J Clin Endocrinol Metab, 88,9:4379–4383.
34.
StenvinkelP, HeimburgerO, LindholmB. 2004. Wasting, but not malnutrition, predicts cardiovascular mortality in end-stage renal disease. Nephrol Dial Transplant, 19,9:2181–2183.
35.
Suhardjono. 2006. Malnutrition-inflammation syndrome in a hemodialysis population: the influence of polymorphic IL-6-174 and IL-10-1082 genes. Acta Med Indones, 38,3:145–149.
36.
SunF, SunY, ZhangD, ZhangJ, SongB, ZhengH. 2010. Association of interleukin-10 gene polymorphism with cachexia in chinese patients with gastric cancer. Ann Clin Lab Sci, 40,2:149–155.
37.
TimashevaYR, NasibullinTR, ZakirovaAN, MustafinaOE. 2008. Association of interleukin-6, interleukin-12, and interleukin-10 gene polymorphisms with essential hypertension in tatars from Russia. Biochem Genet, 46,1–2:64–74.
38.
van HallG, SteensbergA, FischerC, KellerC, MollerK, MoseleyP, PedersenBK. 2008. Interleukin-6 markedly decreases skeletal muscle protein turnover and increases nonmuscle amino acid utilization in healthy individuals. J Clin Endocrinol Metab, 93,7:2851–2858.
39.
VannierE, MillerLC, DinarelloCA. 1992. Coordinated antiinflammatory effects of interleukin 4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist. Proc Natl Acad Sci U S A, 89,9:4076–4080.
40.
VatayA, BeneL, KovacsA, ProhaszkaZ, SzalaiC, RomicsL, FeketeB, KaradiI, FustG. 2003. Relationship between the tumor necrosis factor alpha polymorphism and the serum c-reactive protein levels in inflammatory bowel disease. Immunogenetics, 55,4:247–252.
41.
WypasekE, UndasA, Sniezek-MaciejewskaM, KapelakB, PlicnerD, StepienE, SadowskiJ. 2010. The increased plasma c-reactive protein and interleukin-6 levels in patients undergoing coronary artery bypass grafting surgery are associated with the interleukin-6-174g>c gene polymorphism. Ann Clin Biochem, 47,Pt 4:343–349.
42.
XieG, MyintPK, ZhaoL, LiY, WangH, LiangL, WuY. 2010. Relationship between −592a/c polymorphism of interleukin-10 (IL-10) gene and risk of early carotid atherosclerosis. Int J Cardiol, 143,1:102–104.
43.
YamaguchiS, YamadaY, MetokiN, YoshidaH, SatohK, IchiharaS, KatoK, KameyamaT, YokoiK, MatsuoH, SegawaT, WatanabeS, NozawaY. 2006. Genetic risk for atherothrombotic cerebral infarction in individuals stratified by sex or conventional risk factors for atherosclerosis. Int J Mol Med, 18,5:871–883.
44.
YoshidaT, KatoK, YokoiK, WatanabeS, MetokiN, SatohK, AoyagiY, NishigakiY, NozawaY, YamadaY. 2009. Association of candidate gene polymorphisms with chronic kidney disease in Japanese individuals with hypertension. Hypertens Res, 32,5:411–418.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
